NephrologyOnline.net

Nephrology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Mediexplorer.it

Search results for "Tolvaptan"

The FDA ( Food and Drug Administration ) has advised healthcare professionals of significant liver injury associated with the use of Samsca ( Tolvaptan ). In a double-blind, 3-year, placebo-controlled ...


Tolvaptan ( Samsca ), a diuretic with a new mechanism of action, selectively binds to the vasopressin V2 receptor and inhibits reabsorption of water. Its effect on heart failure is proven, but its ben ...


Vasopressin V2-receptor antagonists may delay disease progression in autosomal dominant polycystic kidney disease ( ADPKD ). Trials with V2-receptor antagonists have been performed predominantly i ...


Tolvaptan ( Samsca ), a diuretic with a new mechanism of action, selectively binds to the vasopressin V2 receptor and inhibits reabsorption of water. Its effect on heart failure is proven, but its ben ...


Vasopressin antagonists increase the serum sodium concentration in patients who have euvolemia and hypervolemia with hyponatremia in the short term ( less than or equal to 30 days ), but their safety ...


The TEMPO 3:4 Trial results suggested that Tolvaptan ( Samsca ) had no effect compared with placebo on albuminuria in autosomal-dominant polycystic kidney disease ( ADPKD ) patients. However, the use ...